-2%
Linez is indicated for the treatment of:
- Nosocomial pneumonia
- Community-acquired pneumonia
- Complicated skin and skin structure infection including diabetic foot infections, without concomitant osteomyelitis
- Uncomplicated skin and skin structure infections
- Vancomycin-resistant Enterococcus faecium infections
Linez is not indicated for the treatment of Gram-negative infections. The safety and efficacy of Linez given for longer than 28 days have not been evaluated in controlled clinical trials.
Linezolid is a synthetic, antibacterial agent belonging to a new class of antibiotics, the oxazolidinones, with in vitro activity against Gram-positive aerobic bacteria, some Gram-positive anaerobic bacteria, and certain Gram-negative bacteria. It selectively inhibits bacterial protein synthesis via a mechanism of action different from that of other antibacterial agents. Linezolid binds to the 23S ribosomal RNA of the 50S subunit of the bacterial ribosome and prevents the formation of a functional 70S initiation complex which is an essential component of the bacterial translation process. The results of time-kill studies have shown Linezolid to be bacteriostatic against enterococci and staphylococci. For streptococci, Linezolid was found to be bactericidal for the majority of strains.